MMP9 and neoplasm: The CA4-loaded nanocarriers could disrupt tumor blood vasculature and selectively enhance MMP9 expression in tumors to promote the accumulation of doxorubicin (Figure 13C), leading to effective treatment of 4T1 and C26 tumors (Figure 13D,E).